Patenting Synthetic Biology -- A Transatlantic Perspective

Investments in synthetic biology research have been ramping up and the field holds significant promise across areas ranging from medicine to renewable energy. As synthetic biology moves forward, it is critical for researchers, technology developers, investors, and public policy makers to understand how the European Patent Office (EPO) and the U.S. Patent and Trademark Office (PTO) will react and respond to the applications covering synthetic biology inventions.

This is a unique opportunity to discuss factors influencing EU and U.S. policies on the evolution of intellectual property protection for synthetic biology with experts from both sides of the Atlantic.